Development of influenza virosome-based synthetic malaria vaccines

Bibliography

• Almond JW. Vaccine renaissance. Nat Rev Micro 2007;5:478-81
   PubMed Web of Science ®Google Scholar
• Vorherr T, Dick F, Sax B. Bachem, a swiss speciality cGMP-manufacturer: history and future prospects. Chimia 2005;59:25-7
   Web of Science ®Google Scholar
• Enshell-Seijffers D, Denisov D, Groisman B, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 2003;334:87-101
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MH. The rational design of biological complexity: a deceptive metaphor. Proteomics 2007;7:965-75
   PubMed Web of Science ®Google Scholar
• Bastian M, Lozano JM, Patarroyo ME, et al. Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Mol Immunol 2004;41:775-84
   PubMed Web of Science ®Google Scholar
• Friede M, Muller S, Briand JP, et al. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes. Vaccine 1994;12:791-7
   PubMed Web of Science ®Google Scholar
• Karle S, Nishiyama Y, Taguchi H, et al. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. Vaccine 2003;21:1213-8
   PubMed Web of Science ®Google Scholar
• Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005;4:827-40
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Casals-Pascual C, Weatherall DJ. The clinical and pathophysiological features of malarial anaemia. Curr Top Microbiol Immunol 2005;295:137-67
   PubMed Web of Science ®Google Scholar
• Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006;28:51-60
   PubMed Web of Science ®Google Scholar
• McGregor IA. The passive transfer of human malarial immunity. Am J Trop Med Hyg 1964;13(Suppl):237-9
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991;45:297-308
   PubMed Web of Science ®Google Scholar
• Perraut R, Marrama L, Diouf B, et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005;191:264-71
   PubMed Web of Science ®Google Scholar
• Gupta S, Snow RW, Donnelly CA, et al. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-3
   PubMed Web of Science ®Google Scholar
• Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002;360:610-7
   PubMed Web of Science ®Google Scholar
• Facer CA, Tanner M. Clinical trials of malaria vaccines: progress and prospects. Adv Parasitol 1997;39:1-68
   PubMed Web of Science ®Google Scholar
• Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006;124:755-66
   PubMed Web of Science ®Google Scholar
• Hviid L. Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity. Microbes Infect 2007;9:772-6
   PubMed Web of Science ®Google Scholar
• Druilhe P, Barnwell JW. Pre-erythrocytic stage malaria vaccines: time for a change in path. Curr Opin Microbiol 2007;10:371-8
   PubMed Web of Science ®Google Scholar
• Genton B, Reed ZH. Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis 2007;20:467-75
   PubMed Web of Science ®Google Scholar
• Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine 2007;25:1567-80
   PubMed Web of Science ®Google Scholar
• Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004;71:239-47
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995;171:1576-85
   PubMed Web of Science ®Google Scholar
• Heppner J, Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005;23:2243-50
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. The Lancet 2001;358:1927-34
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M, et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005;23:4148-57
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-20
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. The Lancet66:2012-8
   Google Scholar
• Genton B, Betuela I, Felger I, et al. A Recombinant blood stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase I/2b Trial in Papua New Guinea. J Infect Dis 2002;185:820-7
   PubMed Web of Science ®Google Scholar
• Fluck C, Schopflin S, Smith T, et al. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 2007;7:44-51
   PubMed Web of Science ®Google Scholar
• Moser C, Amacker M, Kammer AR, et al. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 2007;6:711-21
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Novak-Hofer I, Seelig A, Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog Lipid Res 2000;39:3-18
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Gluck R. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 1999;17:1301-5
   PubMed Web of Science ®Google Scholar
• Poltl-Frank F, Zurbriggen R, Helg A, et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 1999;117:496-503
   PubMed Web of Science ®Google Scholar
• Amacker M, Engler O, Kammer AR, et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 2005;17:695-704
   PubMed Web of Science ®Google Scholar
• Westerfeld N, Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J Pept Sci 2005;11:707-12
   PubMed Web of Science ®Google Scholar
• Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, et al. Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 2006;79:1150-6
   PubMed Web of Science ®Google Scholar
• Kammer AR, Amacker M, Rasi S, et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 2007;25:7065-74
   PubMed Web of Science ®Google Scholar
• Kappe SHI, Buscaglia CA, Nussenzweig V. Plasmodium sporozoite molecular cell biology. Ann Rev Cell Dev Biol 2004;20:29-59
   PubMed Web of Science ®Google Scholar
• Coppi A, Tewari R, Bishop JR, et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2007;2:316-27
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91
   PubMed Web of Science ®Google Scholar
• Dyson HJ, Satterthwait AC, Lerner RA, Wright PE. Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of Plasmodium falciparum by 1H NMR. Biochemistry 1990;29:7828-37
   PubMed Web of Science ®Google Scholar
• Ghasparian A, Moehle K, Linden A, Robinson JA. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun 2006;174-6
   PubMed Web of Science ®Google Scholar
• Okitsu SL, Kienzl U, Moehle K, et al. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol 2007;14:577-87
   PubMed Web of Science ®Google Scholar
• Pfeiffer B, Peduzzi E, Moehle K, et al. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem Int Ed Engl 2003;42:2368-71
   PubMed Web of Science ®Google Scholar
• Moreno R, Jiang L, Moehle K, et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2001;2:838-43
   PubMed Web of Science ®Google Scholar
• Triglia T, Healer J, Caruana SR, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 2000;38:706-18
   PubMed Web of Science ®Google Scholar
• Silvie O, Franetich JF, Charrin S, et al. A Role for Apical Membrane Antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004;279:9490-6
   PubMed Web of Science ®Google Scholar
• Healer J, Crawford S, Ralph S, et al. Independent Translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. Infect Immun 2002;70:5751-8
   PubMed Web of Science ®Google Scholar
• Howell SA, Withers-Martinez C, Kocken CH, et al. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 2001;276:31311-20
   PubMed Web of Science ®Google Scholar
• Howell SA, Hackett F, Jongco AM, et al. Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens. Mol Microbiol 2005;57:1342-56
   PubMed Web of Science ®Google Scholar
• Stowers AW, Kennedy MC, Keegan BP, et al. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002;70:6961-7
   PubMed Web of Science ®Google Scholar
• Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 2000;68:2899-906
   PubMed Web of Science ®Google Scholar
• Coley AM, Gupta A, Murphy VJ, et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathogens 2007;3:e138
   Web of Science ®Google Scholar
• Diaz D, Naegeli M, Rodriguez R, et al. Sequence and diversity of MHC DQA and DQB genes of the owl monkey Aotus nancymaae. Immunogenetics 2000;51:528-37
   PubMed Web of Science ®Google Scholar
• Okitsu SL, Boato F, Mueller MS, et al. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides 2007;28:2051-60
   PubMed Web of Science ®Google Scholar
• James S, Moehle K, Renard A, et al. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chembiochem 2006;7:1943-50
   PubMed Web of Science ®Google Scholar
• Daubenberger CA, Diaz D, Curcic M, et al. Identification and characterization of a conserved, stage-specific gene product of Plasmodium falciparum recognized by parasite growth inhibitory antibodies. Infect Immun 2003;71:2173-81
   PubMed Web of Science ®Google Scholar
• Hodder AN, Drew DR, Epa VC, et al. Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5. J Biol Chem 2003;278:48169-77
   PubMed Web of Science ®Google Scholar
• Epstein JE, Giersing B, Mullen G, et al. Malaria vaccines: are we getting closer? Curr Opin Mol Ther 2007;9:12-24
   PubMed Web of Science ®Google Scholar
• Jiang G, Daubenberger C, Huber W, et al. Sequence diversity of the merozoite surface protein 1 of Plasmodium falciparum in clinical isolates from the Kilombero District, Tanzania. Acta Trop 2000;74:51-61
   PubMed Web of Science ®Google Scholar
• O'Donnell RA, Koning-Ward TF, Burt RA, et al. Antibodies against merozoite surface protein (MSP)-119;are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001;193:1403-12
   PubMed Web of Science ®Google Scholar
• Genton B, Pluschke G. A randomized placebo-controlled Phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2007;2:e1018
   PubMed Web of Science ®Google Scholar
• Mueller MS, Renard A, Boato F, et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun 2003;71:4749-58
   PubMed Web of Science ®Google Scholar
• Okitsu SL, Silvie O, Westerfeld N, et al. A virosomal malaria Peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2007;2:e1278
   PubMed Web of Science ®Google Scholar
• Kappe SHI, Buscaglia CA, Bergman LW, et al. Apicomplexan gliding motility and host cell invasion: overhauling the motor model. Trends Parasitol 2004;20:13-6
   PubMed Web of Science ®Google Scholar
• Peduzzi E, Westerfeld N, Zurbriggen R, et al. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a Phase I subunit malaria vaccine trial. Clin Immunol 2008;doi: 10.1016/j.clim.2008.01.012
   PubMedGoogle Scholar
• Thompson FM, Porter DW, Okitsu SL, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS ONE 2008;3:e1493
   PubMed Web of Science ®Google Scholar
• Gysin J. Animal models: primates. In: Malaria: Parasite Biology, Pathogenesis, and Protection. Shermann IW, editor. Washington DC: American Society for Microbiology; 1998. p. 419-41
   Google Scholar
• Hisaeda H, Maekawa Y, Iwakawa D, et al. Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. Nat Med 2004;10:29-30
   PubMed Web of Science ®Google Scholar
• Long TT, Nakazawa S, Onizuka S, et al. Influence of CD4+CD25+ T cells on Plasmodium berghei NK65 infection in BALB/c mice. Int J Parasitol 2003;33:175-83
   PubMed Web of Science ®Google Scholar
• Nie CQ, Bernard NJ, Schofield L, Hansen DS. CD4+ CD25+ Regulatory T cells suppress CD4+ T-Cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun 2007;75:2275-82
   PubMed Web of Science ®Google Scholar
• Hisaeda H, Tetsutani K, Imai T, et al. Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J Immunol 2008;180:2496-503
   PubMed Web of Science ®Google Scholar
• Walther M, Tongren JE, Andrews L, et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 2005;23:287-96
   PubMed Web of Science ®Google Scholar
• Torcia MG, Santarlasci V, Cosmi L, et al. Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria. Proc Nat Acad Sci USA 2008;105:646-51
   PubMed Web of Science ®Google Scholar
• Williamson WA, Greenwood BM. Impairment of the immune response to vaccination after acute malaria. Lancet 1978;1:1328-9
   PubMed Web of Science ®Google Scholar